Biologics

OrthoPathways Group, Inc. (OPG) Announces New, Novel Instrument Named Bio-Aug FX

Sarasota, FL, November 18, 2010 –(PR.com)– As OrthoPathways Group, Inc. (OPG) continues to pursue new technologies to aid the orthopedically challenged patient, the company reports that they are in the final development stages of a new, novel instrument, Bio-Aug FX, designed to extract stem cells from a patient’s own bone and then reintroduce the same stem cells back into the patient. The stem cells in the human body can turn into other types of cells which are called to the area of the body that needs repair. They are used by orthopedic surgeons to help injuries heal more quickly.

Of all types of cells, stem cells have the greatest potential for promoting healing. Because of the healing capabilities of stem cells, doctors have developed ways to bring stem cells to an injury site faster and in great numbers. This is where the OPG Bio-Aug FX device is used to safely extract the cells and insert them directly into the injury site. This eliminates the time it would normally take for the stem cells to reach the injury on their own, and delivers them in higher concentrations, which ultimately speeds the healing process.

“The use of stem cells in orthopedics will provide yet another way for surgeons to manage complex conditions such as fracture management, cartilage repair, spinal cord injury/fusion, and bone and tissue regeneration. OPG will continue to research stem cell therapies and develop new products to support this technology,” stated OPG President, Steve Bales.

OPG is a medical device company engaged in the development, production and distribution of orthopedic technologies. They provide cost effective, traditional systems to the marketplace, as well as research new science to develop cutting edge, proprietary and patented devices. For further information on OPG visit www.opg.us.com.

OPG is a member of the Global-Med Technologies Group, Inc. (GTG) family of companies located in Sarasota, Florida. Global-Med Technologies Group, Inc. (GTG) is a forward-looking and innovative private equity group focused on helping medical professionals enhance the standard of care for patients worldwide. It is one of only a few firms with a model exclusively focused on the $32 billion worldwide orthopedic and musculoskeletal device industry. For more information on GTG visit www.global-med.us.com

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button